Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2

Part of Pediatric Surgical Oncology 27 items

pubmed.ncbi.nlm.nih.gov

Meera Kotagal

Background: To review race and ethnic group enrollment and outcomes for Wilms tumor (WT) across all 4 risk-assigned therapeutic trials from the current era Children's Oncology Group Renal Tumor Biology and Risk Stratification Protocol, AREN03B2. Study Design: For patients with WT enrolled in AREN03B2 (2006 to 2019), disease and biologic features, therapeutic study-specific enrollment, and event-free (EFS) and overall (OS) 4-year survival were compared between institutionally reported race and ethnic groups. Results: Among 5,146 patients with WT, no statistically significant differences were detected between race and ethnic groups regarding subsequent risk-assigned therapeutic study enrollment, disease stage, histology, biologic factors, or overall EFS or OS, except the following variables: Black children were older and had larger tumors at enrollment, whereas Hispanic children had lower rates of diffuse anaplasia WT and loss of heterozygosity at 1p. The only significant difference in EFS or OS between race and ethnic groups was observed among the few children treated for diffuse anaplasia WT with regimen UH-1 and -2 on high-risk protocol, AREN0321. On this therapeutic arm only, Black children showed worse EFS (hazard ratio = 3.18) and OS (hazard ratio = 3.42). However, this finding was not replicated for patients treated with regimen UH-1 and -2 under AREN03B2 but not on AREN0321. Conclusions: Race and ethnic group enrollment appeared constant across AREN03B2 risk-assigned th

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Mar 2024 · 1 min read

In brief

This study analyzed race and ethnic enrollment patterns and outcomes for 5,146 Wilms tumor patients in the Children's Oncology Group AREN03B2 protocol from 2006-2019. While overall survival showed no significant racial disparities across most treatment groups, Black children with diffuse anaplasia on one specific regimen demonstrated worse outcomes, warranting further investigation into treatment response differences.

Written by the GCMD Library team from the article.

Meera Kotagal

Statements in this article

Among 5,146 patients with Wilms tumor enrolled in AREN03B2 from 2006 to 2019, no statistically significant differences were detected between race and ethnic groups regarding risk-assigned therapeutic study enrollment, disease stage, histology, or biologic factors.
ResearchResults
Black children with Wilms tumor were older at enrollment compared to other race and ethnic groups.
ResearchResults
Black children with Wilms tumor had larger tumors at enrollment compared to other race and ethnic groups.
ResearchResults
Hispanic children with Wilms tumor had lower rates of diffuse anaplasia compared to other race and ethnic groups.
ResearchResults
Hispanic children with Wilms tumor had lower rates of loss of heterozygosity at 1p compared to other race and ethnic groups.
ResearchResults
No statistically significant differences in overall event-free survival or overall survival were detected between race and ethnic groups for Wilms tumor patients enrolled in AREN03B2.
ResearchResults
Black children treated for diffuse anaplasia Wilms tumor with regimen UH-1 and -2 on high-risk protocol AREN0321 showed worse event-free survival with a hazard ratio of 3.18.
ResearchResults
Black children treated for diffuse anaplasia Wilms tumor with regimen UH-1 and -2 on high-risk protocol AREN0321 showed worse overall survival with a hazard ratio of 3.42.
ResearchResults
The survival difference observed in Black children treated with regimen UH-1 and -2 on AREN0321 was not replicated for patients treated with the same regimen under AREN03B2 but not enrolled on AREN0321.
ResearchResults
Race and ethnic group enrollment appeared constant across AREN03B2 risk-assigned therapeutic trials.
ResearchConclusions